Press Releases

TEL AVIV, Israel, Sept. 27, 2018 /PRNewswire/ --  Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH, announced today that Galmed management will provide a corporate update at three upcoming investor conferences in New York City: Cantor Global Healthcare Conference (October 1-3),  the ROTH Battle of the NASH Thrones Investor Conference (October 17), and the Stifel Healthcare Conference (November 13-14). 

Cantor Global Healthcare Conference:
Date: Tuesday, October 2
Time: 9:45am Eastern Time
Location: InterContinental New York Barclay Hotel, Grand Ballroom 2

ROTH Battle of the NASH Thrones Investor Conference:
Date: Wednesday, October 17
Time: 8:00am Eastern Time
Location: Park Hyatt New York Hotel

Stifel Healthcare Conference:
This conference will take place November 13-14 in New York. Details of time and location of Galmed's presentation will be published at http://galmedpharma.investorroom.com/events when available.

About Galmed Pharmaceuticals Ltd.
Galmed is a clinical-stage biopharmaceutical company focused on the development of Aramchol, a first in class, novel, once-daily, oral therapy for the treatment of NASH. Galmed recently announced top-line results of the ARREST Study, a global, double blind, placebo-controlled Phase IIb clinical study designed to evaluate the efficacy and safety of Aramchol in subjects with NASH, who are overweight or obese, and who are pre-diabetic or type-II-diabetic. Galmed is currently preparing for an end of Phase IIb meeting with the FDA to discuss the results of the ARREST Study and a Phase III study protocol, with a view to initiating a Phase III clinical study of Aramchol in 2019.

SOURCE Galmed Pharmaceuticals Ltd.